LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

LGC Clinical Diagnostics Presents Seraseq and ACCURUN Range of Diagnostic Solutions

By LabMedica International staff writers
Posted on 12 Nov 2024
Print article
Image: The Seraseq and ACCURUN range of diagnostic solutions are on display at MEDICA 2024 (Photo courtesy of LGC)
Image: The Seraseq and ACCURUN range of diagnostic solutions are on display at MEDICA 2024 (Photo courtesy of LGC)

LGC Clinical Diagnostics (Middlesex, UK) is presenting its latest diagnostic solutions at this year’s MEDICA, including Seraseq and ACCURUN, which align with the increasing demand for personalized medicine and enhance clinical research capabilities, along with other best-in-class products across the company’s portfolio.

At MEDICA 2024, LGC is providing full access to its product brands including Technopath Clinical Diagnostics (IVD raw materials, independent quality controls, QC software solutions), SeraCare (quality controls, reference materials, biological materials, research), Biochemical Diagnostics (drugs of abuse testing), KOVA International (urinalysis controls), Maine Standards (linearity and calibration verification, calibrators, OEM PT/EQA samples), and The Native Antigen Company (viral and bacterial antigens & antibodies, reagent components).

LGC is highlighting SeraCare’s comprehensive suite of patient-like reference materials that accelerates development, streamlines validation, and ensures confidence in the results of today’s demanding clinical genomics assays. These platform-agnostic, ground-truth reference materials can be used through all development phases to verify actionable and challenging variants as well as complex genomic signatures in patient samples. These ready-to-use reference materials cover clinically relevant variants and all variant types - SNVs, INDELS, CNVs, and RNA fusions. Highly multiplexed, they provide significantly more data per NGS run, saving sequencing costs. They are also available in multiple formats to suit different workflow needs - purified DNA & RNA, ctDNA, encapsulated ctDNA in plasma, and FFPE.

LGC is also presenting SeraCare’s ACCURUN molecular controls and reference materials which are whole-cell or whole-organism external controls that help monitor all aspects of molecular testing methods and provide additional confidence in laboratory test results. A well-designed QC program can help labs avoid costly false-negative or false-positive results. ACCURUN molecular controls effectively detect low-positives closer to assay-specific cutoffs, enabling better detection of assay variability. The powerful ACCURUN controls and reference materials help to ensure complete control over assay performance monitoring.

Related Links:
LGC

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.